Business
Updated Survival Results from BLP25 Liposome Vaccine (L-BLP25) Phase IIb Study from Patients with Stage IIIB Non-Small Cell Lung Cancer (NSCLC) Presented
Updated Survival Results from BLP25 Liposome Vaccine (L-BLP25) Phase IIb Study from Patients with Stage IIIB Non-Small Cell Lung Cancer (NSCLC) Presented.
About this update from Skrr Exploration, Inc.
[{"type":"text","content":"\n\n\n\n\nData Presented As Part of One of Two Poster Presentations at 2005 \nAmerican Society of Clinical Oncology (ASCO) Annual Meeting\n\nEDMONTON, May 16 /CNW/ - Biomira Inc. (Nasdaq:BIOM) (TSX:BRA) of\nEdmonton, Alberta, Canada and Merck KGaA of Darmstadt, Germany, announced\ntoday that a poster discussion on Saturday, May 14, 2005 at the ASCO meeting\ndetailed the updated annual survival results from the Phase IIb NSCLC study in\npatients with Stage IIIB disease. The data were from the trial's last formal\nanalysis that was conducted in November 2004 and discussed in general terms in\nDecember 2004. Dr. Nevin Murray, a Clinical Investigator with the Phase IIb\nstudy, was the lead author on the poster. Dr. Murray is from the BC Cancer\nAgency, Vancouver, British Columbia. His poster was entitled, \"A Liposomal\nMUC1 Vaccine for Treatment of Non-Small Cell Lung Cancer (NSCLC); Updated\nSurvival Results from Patients with Stage IIIB Disease\". Dr. Charles Rudin of\nJohns Hopkins led the discussion portion of the presentation.\nAt the time of the November 2004 survival update, conducted approximately\ntwo years after the last patient had been enrolled in the trial, the median\nsurvival of patients with Stage IIIB locoregional disease who received best\nsupportive care was 13.3 months and that the median survival had not yet been\nreached for those of the same disease stage who received vaccine. This means\nthat more than 50 per cent of the patients on the vaccine arm in this subset\nwere still alive at that time. The difference in survival between the two\ngroups remains non-significant (p(equal sign)0.0924). However, the median\nsurvival of the vaccine arm will be no less than 23 months and the hazard\nratio remains 0.5652 (A hazard ratio of less than one indicates a decrease in\nthe risk of death). The one-year, two-year, and three-year survival\ndifferences continue to suggest a positive survival impact for those who\nreceived vaccine.\n\"Despite the relatively small number of Stage IIIB patients in each arm\nof the study, I believe the data support moving forward with a Phase III\ntrial, to see if we can show a statistically significant advantage for\npatients in the vaccine arm,\" said Dr. Murray. \"I look forward to\nparticipating in that larger study as quickly as possible.\"\n\"We are very encouraged with the results o...